Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor

被引:125
作者
Cole, David K. [1 ]
Yuan, Fang [2 ]
Rizkallah, Pierre J. [1 ,3 ]
Miles, John J. [1 ,4 ]
Gostick, Emma [1 ]
Price, David A. [1 ]
Gao, George F. [5 ]
Jakobsen, Bent K. [6 ]
Sewell, Andrew K. [1 ]
机构
[1] Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England
[3] STFC Daresbury Lab, Warrington WA4 4AD, Cheshire, England
[4] Univ Queensland, Queensland Inst Med Res, Cellular Immunol Lab, Brisbane, Qld 4029, Australia
[5] Chinese Acad Sci, Inst Microbiol, Beijing 100101, Peoples R China
[6] Immunocore Ltd, Abingdon OX14 4RX, Oxon, England
基金
英国生物技术与生命科学研究理事会;
关键词
COMPLEX CLASS-I; TUMOR-REACTIVE CTL; PEPTIDE VACCINES; STRUCTURAL BASIS; ANTIGEN; ALPHA; IMMUNOGENICITY; AFFINITY; CHAIN; USAGE;
D O I
10.1074/jbc.M109.022509
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD8(+) T-cells specific for MART-1-(26-35), a dominant melanoma epitope restricted by human leukocyte antigen (HLA)A* 0201, are exceptionally common in the naive T-cell repertoire. Remarkably, the TRAV12-2 gene is used to encode the T-cell receptor alpha(TCR alpha) chain in > 87% of these T-cells. Here, the molecular basis for this genetic bias is revealed from the structural and thermodynamic properties of an archetypal TRAV12-2-encoded TCR complexed to the clinically relevant heteroclitic peptide, ELAGIGILTV, bound to HLA-A*0201 (A2ELA). Unusually, the TRAV12-2 germ line-encoded regions of the TCR dominate the major atomic contacts with the peptide at the TCR/A2-ELA interface. This "innate" pattern of antigen recognition probably explains the unique characteristics and extraordinary frequencies of CD8(+) T-cell responses to this epitope.
引用
收藏
页码:27281 / 27289
页数:9
相关论文
共 52 条
  • [21] IDENTIFICATION OF THE IMMUNODOMINANT PEPTIDES OF THE MART-1 HUMAN-MELANOMA ANTIGEN RECOGNIZED BY THE MAJORITY OF HLA-A2-RESTRICTED TUMOR-INFILTRATING LYMPHOCYTES
    KAWAKAMI, Y
    ELIYAHU, S
    SAKAGUCHI, K
    ROBBINS, PF
    RIVOLTINI, L
    YANNELLI, JR
    APPELLA, E
    ROSENBERG, SA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) : 347 - 352
  • [22] Kawakami Y, 1997, Int Rev Immunol, V14, P173, DOI 10.3109/08830189709116851
  • [23] A structural basis for the selection of dominant αβ T cell receptors in antiviral immunity
    Kjer-Nielsen, L
    Clements, CS
    Purcell, AW
    Brooks, AG
    Whisstock, JC
    Burrows, SR
    McCluskey, J
    Rossjohn, J
    [J]. IMMUNITY, 2003, 18 (01) : 53 - 64
  • [24] GENETIC-POLYMORPHISM WITHIN HLA-A-ASTERISK-02 - SIGNIFICANT ALLELIC VARIATION REVEALED IN DIFFERENT POPULATIONS
    KRAUSA, P
    BRYWKA, M
    SAVAGE, D
    HUI, KM
    BUNCE, M
    NGAI, JLF
    TEO, DLT
    ONG, YW
    BAROUCH, D
    ALLSOP, CEM
    HILL, AVS
    MCMICHAEL, AJ
    BODMER, JG
    BROWNING, MJ
    [J]. TISSUE ANTIGENS, 1995, 45 (04): : 223 - 231
  • [25] Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties
    Laugel, Bruno
    van den Berg, Hugo A.
    Gostick, Emma
    Cole, David K.
    Wooldridge, Linda
    Boulter, Jonathan
    Milicic, Anita
    Price, David A.
    Sewell, Andrew K.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (33) : 23799 - 23810
  • [26] Leslie A.G. W., 1992, Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography, V26
  • [27] Likelihood-enhanced fast translation functions
    McCoy, AJ
    Grosse-Kunstleve, RW
    Storoni, LC
    Read, RJ
    [J]. ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2005, 61 : 458 - 464
  • [28] Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients
    Meidenbauer, N
    Marienhagen, J
    Laumer, M
    Vogl, S
    Heymann, J
    Andreesen, R
    Mackensen, A
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (04) : 2161 - 2169
  • [29] Engineered T cell receptors and their potential in molecular medicine
    Miles, John J.
    Silins, Sharon L.
    Burrows, Scott R.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2006, 13 (23) : 2725 - 2736
  • [30] Cancer regression in patients after transfer of genetically engineered lymphocytes
    Morgan, Richard A.
    Dudley, Mark E.
    Wunderlich, John R.
    Hughes, Marybeth S.
    Yang, James C.
    Sherry, Richard M.
    Royal, Richard E.
    Topalian, Suzanne L.
    Kammula, Udai S.
    Restifo, Nicholas P.
    Zheng, Zhili
    Nahvi, Azam
    de Vries, Christiaan R.
    Rogers-Freezer, Linda J.
    Mavroukakis, Sharon A.
    Rosenberg, Steven A.
    [J]. SCIENCE, 2006, 314 (5796) : 126 - 129